ATHEALTERITY THERAPEUTICS LTD

Nasdaq alteritytherapeutics.com


$ 2.49 $ 0.25 (11.06 %)    

Friday, 26-Apr-2024 15:45:18 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 2.51
$ 2.34
$ 0.00 x 0
$ 0.00 x 0
$ 2.34 - $ 2.49
$ 1.55 - $ 5.41
87,873
na
102.07M
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alterity-therapeutics-parkinsons-disease-and-multiple-system-atrophy-data-featured-at-the-american-academy-of-neurology-aan-2024-annual-meeting

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

 benchmark-reiterates-speculative-buy-on-alterity-therapeutics-maintains-4-price-target

Benchmark analyst Robert Wasserman reiterates Alterity Therapeutics (NASDAQ:ATHE) with a Speculative Buy and maintains $4 pr...

 alterity-therapeutics-earlier-announced-a-proposed-offering-of-285087720-shares

-ASX Announcement

 alterity-therapeutics-phase-2-data-monitoring-committee-recommends-continuing-clinical-trial-as-planned-after-second-review

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-highlights-successes-in-msa-research-and-plans-for-parkinsons-disease-trials-in-shareholder-letter

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-names-phillip-hains-as-new-chief-financial-officer-effective-january-31-2024

The appointment of Mr. Hains follows the resignation of Kathryn Andrews, who has been CFO since 2014. Ms. Andrews has chosen to...

 why-daktronics-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

 why-gitlab-shares-are-trading-higher-by-over-16-here-are-20-stocks-moving-premarket

Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION